UPDATE 2-US FDA panel weighs antipsychotic drug use in kids

* Advisers weigh if 3 drugs should be approved for kids

* Makers say side effects acceptable in light of benefits

* Consumer groups say data inadequate (Adds company comments on advertising)

By Lisa Richwine

ADELPHI, Md., June 9 (Reuters) - Makers of three blockbuster antipsychotic drugs urged U.S. advisers on Tuesday to recommend approval of the medicines for children as young as 10 with schizophrenia or bipolar disorder.

Eli Lilly and Co's (LLY.N) Zyprexa, AstraZeneca's (AZN.L) Seroquel and Pfizer's (PFE.N) Geodon are sold for treating adults and already are given to youngsters. But winning Food and Drug Administration approval would allow the companies to promote them specifically for children and teens.

Wider approval could boost sales that now top a combined $10 billion annually.

FDA reviewers agreed the drugs seemed effective for younger patients but asked a panel of outside experts to consider risks of weight gain, sleepiness and other reactions. Consumer groups said too little is known about possible long-term problems.

Studies in children showed the types of complications were similar to the ones seen in adults, the manufacturers said.